Compare ACAD & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | BFAM |
|---|---|---|
| Founded | 1993 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | 2000 | 2012 |
| Metric | ACAD | BFAM |
|---|---|---|
| Price | $17.18 | $50.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 9 |
| Target Price | $30.21 | ★ $71.22 |
| AVG Volume (30 Days) | ★ 2.4M | 1.4M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.12 | 40.00 |
| EPS | ★ 0.51 | N/A |
| Revenue | $726,437,000.00 | ★ $1,903,182,000.00 |
| Revenue This Year | $19.55 | $4.61 |
| Revenue Next Year | $13.34 | $3.80 |
| P/E Ratio | $34.47 | ★ N/A |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $15.86 | $49.77 |
| 52 Week High | $30.96 | $105.75 |
| Indicator | ACAD | BFAM |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 29.69 |
| Support Level | $15.86 | N/A |
| Resistance Level | $22.71 | $78.95 |
| Average True Range (ATR) | 1.20 | 1.82 |
| MACD | -0.11 | -0.21 |
| Stochastic Oscillator | 18.38 | 4.38 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Bright Horizons Family Solutions Inc provider of early education and child care, family care solutions, and workforce education services that help working families and client employees personally and professionally. It provides services under multi-year contracts with employers that offer early education and child care, back-up care, and educational advisory services as part of their employee benefits package. The company has three business segments; Full-service center-based child care, Backup care, and Educational advisory services. The majority of the revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, and Others.